BC Week In Review | Nov 25, 2013
Clinical News

Deflux hyaluronic acid/dextranomer regulatory update

FDA approved a PMA supplement for Deflux hyaluronic acid/dextranomer from Salix to include 2 additional injection techniques - single intra-ureteric injection and a double intra-ureteric injection - to treat children with vesicoureteral reflux grades II-IV, a malformation...
BC Week In Review | Nov 14, 2011
Company News

Oceana, Salix deal

Oceana launched Solesta in the U.S. in September. Salix believes peak-year sales for the injectable hyaluronic acid biocompatible, which is also marketed in Europe and Canada, could exceed $500 million. Oceana markets Deflux in over...
BioCentury | Nov 14, 2011
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) lost $5.41 (73%) to $1.96 on Friday after FDA asked for two additional clinical trials before it can approve Iluvien to treat diabetic macular edema (DME). Alimera has rights...
BC Extra | Nov 9, 2011
Company News

Salix to acquire Oceana

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) will acquire Oceana Therapeutics Inc. (Edison, N.J.) for $300 million in cash. Salix will gain Oceana's two marketed products: Solesta for fecal incontinence and Deflux to treat children with vesicoureteral reflux,...
BC Week In Review | May 23, 2011
Company News

Dr. Reddy's, Oceana sales and marketing update

Oceana granted Dr. Reddy's exclusive Indian commercialization rights for genitourinary compound Deflux. The gel of 50 mg/mL dextranomer microspheres in a carrier gel of non-animal 15 mg/mL stabilized hyaluronic acid (HA) is injected submucosally in...
BC Week In Review | Jun 15, 2009
Company News

Oceana, Q-Med deal

Oceana completed its previously announced acquisition of exclusive, worldwide rights to commercialize Q-Med's genitourinary compounds Deflux and Solesta for $60 million up front and $60 million in milestones (see BioCentury, April 27). Oceana Therapeutics Inc....
BC Week In Review | Apr 27, 2009
Company News

Oceana, Q-Med deal

Oceana will acquire exclusive, worldwide rights to commercialize Q-Med's genitourinary compounds Deflux and Solesta for $60 million up front and $60 million in milestones. The deal also includes Q-Med's Q-Med Scandinavia Inc. subsidiary. The subsidiary...
Items per page:
1 - 7 of 7